Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
-$4,138,750 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
2 quarters on record
Derivatives in NAMS
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$16,945,000
PutShares
500,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026PERCEPTIVE ADVISORS LLC holds $5,486,611,234 across 68 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
2,035,986 | $681,627,752 | |
| 2 | SYRE |
Spyre Therapeutics, Inc.
|
4,319,496 | $383,484,854 | |
| 3 | CELC |
Celcuity Inc.
|
3,197,200 | $334,491,064 | |
| 4 | ASND |
Ascendis Pharma A/S
|
1,163,721 | $310,387,665 | |
| 5 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
2,586,295 | $287,156,333 | |
| 6 | ROIV |
Roivant Sciences Ltd.
|
8,085,461 | $286,144,464 | |
| 7 | RLAY |
Relay Therapeutics, Inc.
|
14,106,187 | $263,926,758 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
3,752,574 | $213,183,728 |
All Filings in NAMS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,945,000 | 500,000 | Put | Sole | 2026-08-14 | |
| 2024-03-31 | $4,138,750 | 175,000 | Shares | Sole | 2024-08-06 | |
| No filing history on record for this holder in this stock. | ||||||